Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-13

AUTHORS

Alice Gottlieb, Jordi Gratacos, Ara Dikranian, Astrid van Tubergen, Lara Fallon, Birol Emir, Laraine Aikman, Timothy Smith, Linda Chen

ABSTRACT

Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, > 40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation. More... »

PAGES

121-130

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00296-018-4195-x

DOI

http://dx.doi.org/10.1007/s00296-018-4195-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109891401

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30426237


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antirheumatic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Arthritis, Psoriatic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biological Products", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Europe", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Services Needs and Demand", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Health Surveys", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medication Adherence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Reported Outcome Measures", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Practice Patterns, Physicians'", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time-to-Treatment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Dermatology, New York Medical College at Metropolitan Hospital, 1901 First Avenue, Floor 14B, New York, NY 10021 USA", 
          "id": "http://www.grid.ac/institutes/grid.260917.b", 
          "name": [
            "Department of Dermatology, New York Medical College at Metropolitan Hospital, 1901 First Avenue, Floor 14B, New York, NY 10021 USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gottlieb", 
        "givenName": "Alice", 
        "id": "sg:person.0614321162.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614321162.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Rheumatology, University Hosp\u00ectal Parc Taul\u00ed Sabadell, Barcelona, Spain", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Rheumatology, University Hosp\u00ectal Parc Taul\u00ed Sabadell, Barcelona, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gratacos", 
        "givenName": "Jordi", 
        "id": "sg:person.0672043317.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672043317.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cabrillo Center for Rheumatic Disease, San Diego, CA USA", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Cabrillo Center for Rheumatic Disease, San Diego, CA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dikranian", 
        "givenName": "Ara", 
        "id": "sg:person.01323612515.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323612515.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands", 
          "id": "http://www.grid.ac/institutes/grid.412966.e", 
          "name": [
            "Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Tubergen", 
        "givenName": "Astrid", 
        "id": "sg:person.01173530021.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173530021.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Montreal, QC Canada", 
          "id": "http://www.grid.ac/institutes/grid.421137.2", 
          "name": [
            "Pfizer Inc, Montreal, QC Canada"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fallon", 
        "givenName": "Lara", 
        "id": "sg:person.012636102232.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012636102232.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Emir", 
        "givenName": "Birol", 
        "id": "sg:person.0662376453.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662376453.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Ltd, Sandwich, UK", 
          "id": "http://www.grid.ac/institutes/grid.418566.8", 
          "name": [
            "Pfizer Ltd, Sandwich, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aikman", 
        "givenName": "Laraine", 
        "id": "sg:person.014172437407.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014172437407.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Smith", 
        "givenName": "Timothy", 
        "id": "sg:person.07505653171.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07505653171.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, New York, NY USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, New York, NY USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Linda", 
        "id": "sg:person.011100614171.62", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011100614171.62"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00296-015-3415-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031768143", 
          "https://doi.org/10.1007/s00296-015-3415-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00128071-200506060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010950854", 
          "https://doi.org/10.2165/00128071-200506060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00019053-199304050-00006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027738237", 
          "https://doi.org/10.2165/00019053-199304050-00006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40744-016-0029-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002336273", 
          "https://doi.org/10.1007/s40744-016-0029-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11926-015-0540-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035888225", 
          "https://doi.org/10.1007/s11926-015-0540-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12325-015-0256-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048978189", 
          "https://doi.org/10.1007/s12325-015-0256-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s13075-017-1265-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084252280", 
          "https://doi.org/10.1186/s13075-017-1265-5"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40257-013-0032-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031896048", 
          "https://doi.org/10.1007/s40257-013-0032-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1046/j.1525-1497.2001.016009606.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002964461", 
          "https://doi.org/10.1046/j.1525-1497.2001.016009606.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-13", 
    "datePublishedReg": "2018-11-13", 
    "description": "Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, >\u200940% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00296-018-4195-x", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1093123", 
        "issn": [
          "0172-8172", 
          "1437-160X"
        ], 
        "name": "Rheumatology International", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "39"
      }
    ], 
    "keywords": [
      "patient-reported outcomes", 
      "advanced therapies", 
      "psoriatic arthritis", 
      "treatment patterns", 
      "higher Charlson Comorbidity Index scores", 
      "unmet need", 
      "real-world treatment patterns", 
      "Charlson Comorbidity Index score", 
      "Comorbidity Index score", 
      "overall work impairment", 
      "PsA severity", 
      "severe PsA", 
      "PsA diagnosis", 
      "treatment initiation", 
      "medication adherence", 
      "treatment adherence", 
      "work impairment", 
      "disease burden", 
      "inflammatory diseases", 
      "National Health", 
      "Wellness Survey", 
      "health status", 
      "index score", 
      "therapy", 
      "disease severity", 
      "work productivity", 
      "arthritis", 
      "treatment", 
      "adherence", 
      "lower scores", 
      "severity", 
      "outcomes", 
      "EU5", 
      "scores", 
      "better management", 
      "respondents", 
      "comorbidities", 
      "disease", 
      "PSA", 
      "diagnosis", 
      "impairment", 
      "further work", 
      "demographics", 
      "depression", 
      "United States", 
      "burden", 
      "health", 
      "European countries", 
      "status", 
      "initiation", 
      "need", 
      "assessment", 
      "patterns", 
      "management", 
      "uses", 
      "effect", 
      "survey", 
      "time", 
      "countries", 
      "medium", 
      "employment", 
      "Europe", 
      "state", 
      "work", 
      "productivity", 
      "PsA real-world treatment patterns", 
      "EU5 respondents"
    ], 
    "name": "Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe", 
    "pagination": "121-130", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109891401"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00296-018-4195-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30426237"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00296-018-4195-x", 
      "https://app.dimensions.ai/details/publication/pub.1109891401"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_782.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00296-018-4195-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4195-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4195-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4195-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00296-018-4195-x'


 

This table displays all metadata directly associated to this object as RDF triples.

306 TRIPLES      22 PREDICATES      119 URIs      102 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00296-018-4195-x schema:about N3bc5694dd76941d0b667b03ba93ee8da
2 N3e418b6bea1546e8a2c9abe002c4a998
3 N44a094b4cce9439da10d23ef1e2801ae
4 N79911ec36901408ab76182b4c0d682fa
5 N7ecb2cd3fb4943bc82fea6742e69374c
6 N7febe11d33a242ef957e1ee7adb2172c
7 N85df7d2ef83e41a99c2a06410dd4e71f
8 N9e2336917ff6453caf43bdb7674e965c
9 Na5ea7f05476e40568163253659da9343
10 Naf28123a20984acb8d709dbc4d3b99f5
11 Nc5461a9cad944b2c995f4a99900d6e66
12 Ncb541a7e0812483d8e27d0809fc65875
13 Nd7653b26a6a04c7499dcafdc9e63342f
14 Ne8649aecca3f4c1aae59cf940bf6a597
15 Nf065efd9c73c40ca996da7b8ab9669ac
16 Nf1886ce7c49947258ac4f275619d9601
17 Nf196e9aad4dd4a1186575ec9d5995156
18 anzsrc-for:11
19 anzsrc-for:1117
20 schema:author Nb4a52e7f2f03489489be87958567d407
21 schema:citation sg:pub.10.1007/s00296-015-3415-x
22 sg:pub.10.1007/s11926-015-0540-1
23 sg:pub.10.1007/s12325-015-0256-7
24 sg:pub.10.1007/s40257-013-0032-x
25 sg:pub.10.1007/s40744-016-0029-z
26 sg:pub.10.1046/j.1525-1497.2001.016009606.x
27 sg:pub.10.1186/s13075-017-1265-5
28 sg:pub.10.2165/00019053-199304050-00006
29 sg:pub.10.2165/00128071-200506060-00005
30 schema:datePublished 2018-11-13
31 schema:datePublishedReg 2018-11-13
32 schema:description Psoriatic arthritis (PsA) is a chronic, inflammatory disease. The effects of PsA real-world treatment patterns on patient-reported outcomes in the US and 5 European countries (EU5; France, Germany, Italy, Spain, UK) were evaluated. Respondents from the 2016 National Health and Wellness Survey received advanced therapies (e.g., biologic disease-modifying antirheumatic drugs [DMARDs]), other therapies, (e.g., conventional synthetic DMARDs), or no treatment. Assessments included demographics, disease severity (patient-reported), comorbidities (Charlson Comorbidity Index), health status (Short Form-36 Health Survey), depression (Patient Health Questionnaire-9), work productivity (Work Productivity and Activity Index), and treatment adherence (Morisky Medication Adherence Scale-8). Overall, 1037 respondents from the US and 947 respondents from the EU5 were included. Of these, 21.7% US and 7.3% EU5 respondents received advanced therapies; 16.6% and 28.5%, other therapies; and 61.7% and 64.2%, no treatment, respectively. During treatment with advanced or other therapies, 40.8-54.7% US and 57.7-58.9% EU5 respondents self-reported moderate or severe PsA. Respondents receiving advanced therapies had the highest Charlson Comorbidity Index score (US, 1.25; EU5, 1.42); the lowest scores were with no treatment (0.52 and 0.49, respectively). Employment was lowest with other therapies (US, 47.7%; EU5, 41.1%). Overall work impairment was reported by 57.9% US and 62.6% EU5 respondents receiving advanced therapies. Medication adherence was generally low in the US and medium in the EU5 (Morisky Medication Adherence Scale-8: low, US 40.1-46.7%, EU5, 29.0-35.2%; medium, US 29.3-36.1%, EU5 37.8-49.3%; high, US 23.8-24.0%; EU5, 21.7-27.0%). Advanced and other therapies reduced PsA severity; however, > 40% of respondents reported moderate or severe PsA during treatment. Better management and adherence may reduce unmet need and disease burden. Further work is required to improve PsA diagnosis and time to treatment initiation.
33 schema:genre article
34 schema:inLanguage en
35 schema:isAccessibleForFree true
36 schema:isPartOf N6d3e4dd861184d8a95d6ebb2be4eec3e
37 N792bd19821514f05866f76f2de657db3
38 sg:journal.1093123
39 schema:keywords Charlson Comorbidity Index score
40 Comorbidity Index score
41 EU5
42 EU5 respondents
43 Europe
44 European countries
45 National Health
46 PSA
47 PsA diagnosis
48 PsA real-world treatment patterns
49 PsA severity
50 United States
51 Wellness Survey
52 adherence
53 advanced therapies
54 arthritis
55 assessment
56 better management
57 burden
58 comorbidities
59 countries
60 demographics
61 depression
62 diagnosis
63 disease
64 disease burden
65 disease severity
66 effect
67 employment
68 further work
69 health
70 health status
71 higher Charlson Comorbidity Index scores
72 impairment
73 index score
74 inflammatory diseases
75 initiation
76 lower scores
77 management
78 medication adherence
79 medium
80 need
81 outcomes
82 overall work impairment
83 patient-reported outcomes
84 patterns
85 productivity
86 psoriatic arthritis
87 real-world treatment patterns
88 respondents
89 scores
90 severe PsA
91 severity
92 state
93 status
94 survey
95 therapy
96 time
97 treatment
98 treatment adherence
99 treatment initiation
100 treatment patterns
101 unmet need
102 uses
103 work
104 work impairment
105 work productivity
106 schema:name Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe
107 schema:pagination 121-130
108 schema:productId N3809c89699cd41c18bf27c2d73d5145f
109 N6ac5f42632434f0aa62c05ac31c077c2
110 N7814ac7e936b4924a340fefbf96804dc
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109891401
112 https://doi.org/10.1007/s00296-018-4195-x
113 schema:sdDatePublished 2021-11-01T18:33
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Ndb4f33d191274f959a0d19f62f93a77d
116 schema:url https://doi.org/10.1007/s00296-018-4195-x
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N3809c89699cd41c18bf27c2d73d5145f schema:name doi
121 schema:value 10.1007/s00296-018-4195-x
122 rdf:type schema:PropertyValue
123 N3bc5694dd76941d0b667b03ba93ee8da schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Time-to-Treatment
125 rdf:type schema:DefinedTerm
126 N3e418b6bea1546e8a2c9abe002c4a998 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Female
128 rdf:type schema:DefinedTerm
129 N44a094b4cce9439da10d23ef1e2801ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Adult
131 rdf:type schema:DefinedTerm
132 N6ac5f42632434f0aa62c05ac31c077c2 schema:name pubmed_id
133 schema:value 30426237
134 rdf:type schema:PropertyValue
135 N6d3e4dd861184d8a95d6ebb2be4eec3e schema:volumeNumber 39
136 rdf:type schema:PublicationVolume
137 N7814ac7e936b4924a340fefbf96804dc schema:name dimensions_id
138 schema:value pub.1109891401
139 rdf:type schema:PropertyValue
140 N792bd19821514f05866f76f2de657db3 schema:issueNumber 1
141 rdf:type schema:PublicationIssue
142 N79911ec36901408ab76182b4c0d682fa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Europe
144 rdf:type schema:DefinedTerm
145 N7a30c1bc8dae4df680b7da064eed6d37 rdf:first sg:person.0662376453.20
146 rdf:rest Naf9567c60b764016afbfa9add686c725
147 N7ecb2cd3fb4943bc82fea6742e69374c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Biological Products
149 rdf:type schema:DefinedTerm
150 N7febe11d33a242ef957e1ee7adb2172c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name United States
152 rdf:type schema:DefinedTerm
153 N85df7d2ef83e41a99c2a06410dd4e71f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
154 schema:name Male
155 rdf:type schema:DefinedTerm
156 N8f2c3dfb51ca4edd99fcdbb5317ff96a rdf:first sg:person.012636102232.04
157 rdf:rest N7a30c1bc8dae4df680b7da064eed6d37
158 N9e2336917ff6453caf43bdb7674e965c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Medication Adherence
160 rdf:type schema:DefinedTerm
161 Na5ea7f05476e40568163253659da9343 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Health Services Needs and Demand
163 rdf:type schema:DefinedTerm
164 Naf28123a20984acb8d709dbc4d3b99f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Arthritis, Psoriatic
166 rdf:type schema:DefinedTerm
167 Naf9567c60b764016afbfa9add686c725 rdf:first sg:person.014172437407.36
168 rdf:rest Nc5422e1b3bbc46dc963e98a3d026336d
169 Nb4a52e7f2f03489489be87958567d407 rdf:first sg:person.0614321162.29
170 rdf:rest Nc8a92da21577428a9ce6c821d1ccf2f1
171 Nc5422e1b3bbc46dc963e98a3d026336d rdf:first sg:person.07505653171.90
172 rdf:rest Nee1539e63c8b49a285e788b6fdcc3165
173 Nc5461a9cad944b2c995f4a99900d6e66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Practice Patterns, Physicians'
175 rdf:type schema:DefinedTerm
176 Nc8a92da21577428a9ce6c821d1ccf2f1 rdf:first sg:person.0672043317.54
177 rdf:rest Ncb77c72c979b4ed5bee037191a1571b0
178 Ncb541a7e0812483d8e27d0809fc65875 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Humans
180 rdf:type schema:DefinedTerm
181 Ncb77c72c979b4ed5bee037191a1571b0 rdf:first sg:person.01323612515.50
182 rdf:rest Ne32c861a2b3a41d5849332b0bf63ecb5
183 Nd7653b26a6a04c7499dcafdc9e63342f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Health Surveys
185 rdf:type schema:DefinedTerm
186 Ndb4f33d191274f959a0d19f62f93a77d schema:name Springer Nature - SN SciGraph project
187 rdf:type schema:Organization
188 Ne32c861a2b3a41d5849332b0bf63ecb5 rdf:first sg:person.01173530021.96
189 rdf:rest N8f2c3dfb51ca4edd99fcdbb5317ff96a
190 Ne8649aecca3f4c1aae59cf940bf6a597 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Aged
192 rdf:type schema:DefinedTerm
193 Nee1539e63c8b49a285e788b6fdcc3165 rdf:first sg:person.011100614171.62
194 rdf:rest rdf:nil
195 Nf065efd9c73c40ca996da7b8ab9669ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Antirheumatic Agents
197 rdf:type schema:DefinedTerm
198 Nf1886ce7c49947258ac4f275619d9601 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Middle Aged
200 rdf:type schema:DefinedTerm
201 Nf196e9aad4dd4a1186575ec9d5995156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Patient Reported Outcome Measures
203 rdf:type schema:DefinedTerm
204 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
205 schema:name Medical and Health Sciences
206 rdf:type schema:DefinedTerm
207 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
208 schema:name Public Health and Health Services
209 rdf:type schema:DefinedTerm
210 sg:journal.1093123 schema:issn 0172-8172
211 1437-160X
212 schema:name Rheumatology International
213 schema:publisher Springer Nature
214 rdf:type schema:Periodical
215 sg:person.011100614171.62 schema:affiliation grid-institutes:grid.410513.2
216 schema:familyName Chen
217 schema:givenName Linda
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011100614171.62
219 rdf:type schema:Person
220 sg:person.01173530021.96 schema:affiliation grid-institutes:grid.412966.e
221 schema:familyName van Tubergen
222 schema:givenName Astrid
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173530021.96
224 rdf:type schema:Person
225 sg:person.012636102232.04 schema:affiliation grid-institutes:grid.421137.2
226 schema:familyName Fallon
227 schema:givenName Lara
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012636102232.04
229 rdf:type schema:Person
230 sg:person.01323612515.50 schema:affiliation grid-institutes:None
231 schema:familyName Dikranian
232 schema:givenName Ara
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01323612515.50
234 rdf:type schema:Person
235 sg:person.014172437407.36 schema:affiliation grid-institutes:grid.418566.8
236 schema:familyName Aikman
237 schema:givenName Laraine
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014172437407.36
239 rdf:type schema:Person
240 sg:person.0614321162.29 schema:affiliation grid-institutes:grid.260917.b
241 schema:familyName Gottlieb
242 schema:givenName Alice
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0614321162.29
244 rdf:type schema:Person
245 sg:person.0662376453.20 schema:affiliation grid-institutes:grid.410513.2
246 schema:familyName Emir
247 schema:givenName Birol
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0662376453.20
249 rdf:type schema:Person
250 sg:person.0672043317.54 schema:affiliation grid-institutes:None
251 schema:familyName Gratacos
252 schema:givenName Jordi
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0672043317.54
254 rdf:type schema:Person
255 sg:person.07505653171.90 schema:affiliation grid-institutes:grid.410513.2
256 schema:familyName Smith
257 schema:givenName Timothy
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07505653171.90
259 rdf:type schema:Person
260 sg:pub.10.1007/s00296-015-3415-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031768143
261 https://doi.org/10.1007/s00296-015-3415-x
262 rdf:type schema:CreativeWork
263 sg:pub.10.1007/s11926-015-0540-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035888225
264 https://doi.org/10.1007/s11926-015-0540-1
265 rdf:type schema:CreativeWork
266 sg:pub.10.1007/s12325-015-0256-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048978189
267 https://doi.org/10.1007/s12325-015-0256-7
268 rdf:type schema:CreativeWork
269 sg:pub.10.1007/s40257-013-0032-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1031896048
270 https://doi.org/10.1007/s40257-013-0032-x
271 rdf:type schema:CreativeWork
272 sg:pub.10.1007/s40744-016-0029-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1002336273
273 https://doi.org/10.1007/s40744-016-0029-z
274 rdf:type schema:CreativeWork
275 sg:pub.10.1046/j.1525-1497.2001.016009606.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002964461
276 https://doi.org/10.1046/j.1525-1497.2001.016009606.x
277 rdf:type schema:CreativeWork
278 sg:pub.10.1186/s13075-017-1265-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084252280
279 https://doi.org/10.1186/s13075-017-1265-5
280 rdf:type schema:CreativeWork
281 sg:pub.10.2165/00019053-199304050-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027738237
282 https://doi.org/10.2165/00019053-199304050-00006
283 rdf:type schema:CreativeWork
284 sg:pub.10.2165/00128071-200506060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010950854
285 https://doi.org/10.2165/00128071-200506060-00005
286 rdf:type schema:CreativeWork
287 grid-institutes:None schema:alternateName Cabrillo Center for Rheumatic Disease, San Diego, CA USA
288 Department of Rheumatology, University Hospìtal Parc Taulí Sabadell, Barcelona, Spain
289 schema:name Cabrillo Center for Rheumatic Disease, San Diego, CA USA
290 Department of Rheumatology, University Hospìtal Parc Taulí Sabadell, Barcelona, Spain
291 rdf:type schema:Organization
292 grid-institutes:grid.260917.b schema:alternateName Department of Dermatology, New York Medical College at Metropolitan Hospital, 1901 First Avenue, Floor 14B, New York, NY 10021 USA
293 schema:name Department of Dermatology, New York Medical College at Metropolitan Hospital, 1901 First Avenue, Floor 14B, New York, NY 10021 USA
294 rdf:type schema:Organization
295 grid-institutes:grid.410513.2 schema:alternateName Pfizer Inc, New York, NY USA
296 schema:name Pfizer Inc, New York, NY USA
297 rdf:type schema:Organization
298 grid-institutes:grid.412966.e schema:alternateName Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
299 schema:name Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
300 rdf:type schema:Organization
301 grid-institutes:grid.418566.8 schema:alternateName Pfizer Ltd, Sandwich, UK
302 schema:name Pfizer Ltd, Sandwich, UK
303 rdf:type schema:Organization
304 grid-institutes:grid.421137.2 schema:alternateName Pfizer Inc, Montreal, QC Canada
305 schema:name Pfizer Inc, Montreal, QC Canada
306 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...